Abstract
The Middle East pharmaceutical market is diverse, with a significant presence
of leading global players alongside domestic pharmaceutical companies such as
Ibrahim, Bilim and Deva. The market dynamics are further shaped by the
presence of several leading suppliers of branded generics and APIs (active
pharmaceutical ingredients) such as Teva, Hikma, Ibrahim, etc. Although,
Middle East countries were a late entrant to the biotech sector, countries
like Turkey, Saudi Arabia, UAE and Israel has made a dramatic progress in
recent years, which was mainly due to several government initiatives.
Moreover, several public-private partnerships also boosted the growth of
pharmaceutical sector in the Middle East region. ' The Middle Eastern
Pharmaceutical Market Outlook To 2014' report gives a strategic insight into
the leading ATC classes, brands and key pharmaceutical players in the Middle
East market. The top 10 brands and companies were selected from a pool of
Middle East drug majors and were later rank-ordered and profiled based on
revenues and market share presence in the Middle East market in 2008. This
report makes a wide-ranging assessment of the marketed product portfolio, R&D
pipeline, market share data, sales forecast and competitive landscape for the
major players in the Middle East market. Furthermore, it highlights the key
market and R&D trends that may influence treatment sales; with a thorough
analysis of the competitive dynamics of leading brands within each country and
indication, in order to enable the reader to identify growth trends, key drug
classes and leading players through 2014.
Table of Contents
Executive Summary
|
[市場調
查報告
�
娭 2014年之前中東地區藥品市場�
w測：政�
池藿牷B市場結構、競爭動向、成長機會 Et Meetinggoodlookingexposed Pl Trailere Char N Meeting Good Looking Exposed